Stoke Therapeutics (STOK) Change in Acquisitions & Divestments (2022 - 2026)

Stoke Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $60.9 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 85.67% year-over-year to $60.9 million in Q1 2026; TTM through Mar 2026 was $164.7 million, a 98.89% increase from a year earlier, with the FY2025 full-year figure at $136.6 million, up 127.63% from the prior year.
• Change in Acquisitions & Divestments grew to $60.9 million in Q1 2026 per STOK's latest filing, from $37.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $79.0 million in Q3 2022 and bottomed at $9.0 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $31.4 million (2024), against an average of $32.8 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 491.67% in 2023 and sank 81.22% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $18.0 million in 2022, then retreated by 16.8% to $15.0 million in 2023, then soared by 100.0% to $30.0 million in 2024, then grew by 24.66% to $37.4 million in 2025, then jumped by 62.84% to $60.9 million in 2026.
• Per Business Quant, the three latest STOK Change in Acquisitions & Divestments figures stand at $60.9 million (Q1 2026), $37.4 million (Q4 2025), and $33.2 million (Q3 2025).